Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced the appointment of Brian Kim as Chief Executive Officer. With over two decades of experience in the life sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company. His experience in driving organizational transformation and large-scale commercial growth, coupled with his deep knowledge of the life sciences sector, signifies Mission Bio’s commitment to expanding into clinical applications with biopharma partners.
Brian’s track record is a testament to his ability to create innovative customer solutions for clinical end markets and build valuable, high-growth companies. As Chief Executive Officer of Fortis Life Sciences, he founded and grew the company into a leading business-to-business provider of proprietary reagents for clinical customers.
Also Read : Synlogic Announces Contract with the Air Force Research Lab
As Managing Director of the Biosearch Technologies division of LGC, a UK-based private equity-backed life sciences tools company, Brian spearheaded the expansion into diagnostics and therapeutic end markets, resulting in the successful sale of the company in 2020. As President of PerkinElmer’s Life Science and Tools division, he revitalized product innovation, revamped the commercial organization, and returned the business to growth.
“Brian’s experience in life sciences tools commercialization and clinical end markets fits exactly with Mission Bio’s vision to advance single-cell multiomics into translational research and clinical applications,” said Stuart Essig, PhD, chairman of the board at Mission Bio. “He comes at an exciting stage in the company’s evolution when our technology is beginning to make measurable progress in helping improve patient health outcomes.”
“As I step into my new role, my first objective is to support the amazing team and the growing body of customer applications built around the Tapestri platform,” said Brian. “I am committed to the founding vision of establishing Mission Bio as an essential part of the new standard for personalized medicine and targeted therapies.”
SOURCE : BusinessWire